Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study.

Journal:
American Journal of Respiratory and Critical Care Medicine
Published:
DOI:
10.1164/rccm.202502-0512oc
Affiliations:
21
Authors:
18
Go to article
Institutions Authors Share
Vertex Pharmaceuticals, United States of America (USA)
4.000000
 0.22
Oregon Health and Science University (OHSU), United States of America (USA)
1.000000
 0.06
University of Toronto (U of T), Canada
1.000000
 0.06
BC Children's Hospital and Sunny Hill Health Centre for Children, PHSA, Canada
1.000000
 0.06
The University of North Carolina at Chapel Hill (UNC), United States of America (USA)
1.000000
 0.06
University Hospitals Cleveland Medical Center, CWRU, United States of America (USA)
1.000000
 0.06
Seattle Children's Hospital, United States of America (USA)
1.000000
 0.06
St. Vincent's University Hospital, Ireland
1.000000
 0.06
St. Michael's Hospital, Canada
1.000000
 0.06
National Jewish Health (NJH), United States of America (USA)
1.000000
 0.06
Queensland Children's Hospital (QCH), CHQ, Australia
0.500000
 0.03
The University of Queensland (UQ), Australia
0.500000
 0.03
Ann and Robert H. Lurie Children's Hospital of Chicago, NU, United States of America (USA)
0.500000
 0.03
Northwestern University (NU), United States of America (USA)
0.500000
 0.03
Royal College of Surgeons in Ireland (RCSI), Ireland
0.500000
 0.03
Children’s Health Ireland (CHI), Ireland
0.500000
 0.03
Imperial College London (ICL), United Kingdom (UK)
0.500000
 0.03
Royal Brompton Hospital, United Kingdom (UK)
0.500000
 0.03
Charité - University Medicine Berlin, Germany
0.333333
 0.02
DZKJ partner site Berlin, Germany
0.333333
 0.02
DZL associated partner site Berlin, Germany
0.333333
 0.02
Interested in Cardiovascular Medicine and Haematology?